**Claims:**

1. A bispecific anti-HIV gp120-binding protein comprising (i) an anti-V3 bNAb comprising two heavy chains and two light chains; and (ii) at least one CD4 domain, wherein the CD4 domain is attached directly or by a linker to the N-terminus or C-terminus of one of the anti-V3 bNAb heavy chains or light chains.
2. The bispecific protein as claimed in claim 1, wherein the CD4 domain is attached via a linker to the N-terminus or C-terminus of one or both anti-V3 bNAb heavy chains.
3. The bispecific protein as claimed in claim 1, wherein the CD4 domain is attached via a linker to the N-terminus or C-terminus of one or both anti-V3 bNAb light chains.
4. The bispecific protein as claimed in claim 1, further comprising at least four CD4 domains.
5. The bispecific protein as claimed in claim 4, wherein the C-terminus of the first and second CD4 domains are attached by a linker to the N-terminus of each of the anti-V3 heavy chains, and wherein the C-terminus of the third and fourth CD4 domains are attached by a linker to the N-terminus of each of the anti-V3 light chains.
6. The bispecific protein as claimed in any one of claims 1 to 5, wherein the linker is selected from the group consisting of SEQ ID NOs: 90 to 95.
7. The bispecific protein as claimed in claim 6, wherein the linker is SEQ ID NO:90.
8. The bispecific protein as claimed in any one of claims 1 to 7, wherein the CD4 domain is selected from the group consisting of SEQ ID NO:1-21.
9. The bispecific protein as claimed in claim 8, wherein the CD4 domain is SEQ ID NO:11.
10. The bispecific protein as claimed in any one of claims 1 to 9, wherein the two heavy chains comprise a variable heavy (VH) domain of SEQ ID NO:58 and the two light chains comprise a variable light (VL) domain of SEQ ID NO:59 or SEQ ID NO:60.
11. The bispecific protein as claimed in any one of claims 1 to 10, wherein the anti-V3 bNAb is selected from the group consisting of bNAb1, bNAb1*, bNAb2, bNAb3, bNAb4, bNAb5 and bNAb6 as set forth in Table 2.
12. The bispecific protein as claimed in claim 11, wherein the anti-V3 bNAb is bNAb1.
13. The bispecific protein as claimed in any one of claims 1 to 12, wherein the anti-V3 bNAb Fc comprises LS.
14. An anti-HIV gp120-binding protein having two identical heavy chains and two identical light chains, comprising or consisting of:
    a heavy chain that is at least 95% identical to SEQ ID NO:121 and
    a light chain that is at least 95% identical to SEQ ID NO:63.
15. An anti-HIV gp120-binding protein consisting of two heavy chains of SEQ ID NO:121 and two light chains of SEQ ID NO:63.

16. A pharmaceutical composition comprising the anti-HIV gp120-binding protein as defined in any one of the preceding claims and a pharmaceutically acceptable excipient.
17. An anti-HIV gp120-binding protein according to any one of claims 1 to 15, or a pharmaceutical composition according to claim 16, for use in treating or preventing an HIV infection in a human.
18. Use of an anti-HIV gp120-binding protein according to any one of claims 1 to 15, or a pharmaceutical composition according to claim 16, in the manufacture of a medicament for treating or preventing an HIV infection in a human.
19. A kit comprising in separate containers: an anti-HIV gp120-binding protein according to any one of claims 1 to 15 and an anti-viral drug that inhibits cellular entry, replication, or transcription of HIV in a human.
20. The kit as claimed in claim 19, wherein the antiviral drug is selected from the group consisting of: Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Entry Inhibitors, Integrase Strand Transfer Inhibitors (INSTI), Maturation Inhibitors (MIs), Capsid Inhibitors (CIs) and Nucleoside Reverse Transcriptase Translocation Inhibitors (NRTTIs)
21. The kit as claimed in claim 20, wherein the antiviral drug is an INSTI.
22. The kit as claimed in claim 21, wherein the INSTI is dolutegravir or cabotegravir.
23. A nucleic acid sequence that encodes an anti-HIV gp120-binding protein according to any one of claims 1 to 15.
24. An expression vector that comprises the nucleic acid sequence of claim 23.
25. A host cell that comprises the nucleic acid sequence of claim 23 or the expression vector of claim 24.
26. A host cell that comprises two expression vectors:
    a first expression vector comprising a nucleic acid sequence encoding a heavy chain of SEQ ID NO:121; and
    a second expression vector comprising a nucleic acid sequence encoding a light chain of SEQ ID NO:63.
27. A method of producing an anti-HIV gp120-binding protein, comprising culturing the host cell as defined in claim 25 or 26 under conditions suitable for expression of said nucleic acid sequence or vector, whereby an anti-HIV gp120-binding protein is produced.
28. A soluble CD4 domain having a Tm above 70 ºC.

29. A soluble CD4 domain comprising one or more stabilizing mutations selected from the group consisting of K8C, K8I, K8V, T11C, E13C, K21C, Q25E, H27C, H27D, G38C, N52W, R58N, R58T, R58V, L61M, G65C, I70C, K72C, E87G, E91H, E91Q, and G99C.
30. The soluble CD4 domain of claim 28 or claim 29 having a Tm of between 70 ºC and 95 ºC.
31. The soluble CD4 domain of claim 28 having a Tm of about 90 ºC.
32. The soluble CD4 domain of any one of claims 28 to 31, comprising K8C and G99C.
33. The soluble CD4 domain of any one of claims 28 to 31, comprising K8I.
34. The soluble CD4 domain of any one of claims 28 to 31, comprising K8V.
35. The soluble CD4 domain of any one of claims 28 to 34, comprising T11C and K72C
36. The soluble CD4 domain of any one of claims 28 to 35, comprising any one of SEQ ID NOs:5-21.
37. The soluble CD4 domain of claim 36, comprising SEQ ID NO:11.
38. The soluble CD4 domain of any one of claims 28 to 37, wherein the CD4 domain is fused directly or via a linker to a human Fc domain.
39. The soluble CD4 domain of claim 38, wherein the Fc domain comprises LS.
40. The soluble CD4 domain of claim 38 or claim 39, wherein the linker is selected from the group consisting of SEQ ID NOs:90-95.